Aurobindo Pharma has got final approval for two of its Abbreviated New Drug Applications (ANDAs) - Stavudine capsules and Stavudine oral solutions - from US Food and Drug Administration (USFDA), a company release said.
These drugs fall under the Anti-Retroviral (ARV) segment and will be used for treatment of HIV.
Aurobindo now has 62 final and 24 tentative ANDA approvals from USFDA.